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Abstract
Background: Sexually transmitted infections (STIs) are a significant global public health issue that cause a high
burden of disease, especially in low- and middle-income countries. Screening of key populations and early and
accurate diagnosis of infection are critical. Testing for syphilis, Chlamydia trachomatis, Neisseria gonorrhoeae,
Trichomonas vaginalis, curable STIs, as well as the human papillomavirus (HPV), is frequently unavailable in low-
resource settings. Tests for these STIs that can be used at the point of patient care (POCTs) are needed.
In recent years, there has been increased attention for STI POCTs, but technical guidance, financial resources and
advocacy for additional platforms/tests are required in order to foster the development of STI POCTs. The WHO
Department of Sexual and Reproductive Health and Research (SRH) has developed target product profiles (TPPs), a
form of technical guidance, for these STI diagnostics.
Methods: SRH conducted a survey of selected companies that are developing POCTs for one or more of the STIs
mentioned above to better understand how these TPPs influence the diagnostic development process – to assess
their impact.
Results: Survey respondents indicated that the STI POCT TPPs provided good guidance with respect to
performance expectations and operational characteristics for the tests/platforms. In particular, optimal metrics for
sensitivity, specificity, sample types, and time to result were considered to be very useful.
Respondents also suggested ways to improve the relevance of the STI POCT TPPs. For example, since it is often not
possible for developers to achieve every desired standard, it would be useful to prioritize each performance/
operational characteristic of the test and to provide a rationale as to why certain characteristics are considered
important.
Respondents also emphasized the need to encourage industry participation in the TPP development process and
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to find creative ways, including via targeted emails, a WHO webpage directed at industry, or a coordinated
communications plan to increase awareness of the TPPs.
Conclusions: Companies value the STI POCT TPPs and want them to continue. In order to maximize impact, WHO
should consider the proposals from the manufacturers in the interest of increasing and accelerating access to STI
diagnostics and treatment in low-resource settings.
Keywords: Sexually transmitted infections, Diagnostics, Point of care tests, Target product profiles, STI-testing,
Pharmaceutical companies, Diagnostic manufacturers, Access to health, STI-strategy
Background
Sexually transmitted infections (STIs) continue to be a
significant global public health issue, with an estimated
378 million people in 2016 becoming infected with one
of 4 curable STIs: syphilis, Chlamydia trachomatis (CT),
Neisseria gonorrhoeae (NG), and Trichomonas vaginalis
(TV) [1]. In addition, more than 291 million women
have a human papillomavirus (HPV) [1].
STIs cause a high burden of disease; they facilitate
transmission of human immunodeficiency virus (HIV)
and are associated with the development of certain can-
cers [1, 2]. Syphilis has particularly profound conse-
quences for pregnant women, causing infant mortality as
well as preterm or low weight births [3, 4]. Furthermore,
CT and NG are consistently associated with tubal factor
infertility and pelvic inflammatory disease [5, 6], and, to-
gether with syphilis, their sequelae may thereby contrib-
ute to subfertility and infertility [3, 5, 6].
A large proportion of STI cases are asymptomatic,
confounding syndromic management of these infections
using treatment algorithms based on the presence of
syndromes and symptoms rather than testing. Syn-
dromic management of STIs is often used in low- and
middle-income countries (LMICs), which bear more
than 90% of the global STI burden [7], but this method
often fails and lacks treatment accuracy [8]. Screening
key populations and early and accurate diagnosis of in-
fection via testing are important to provide appropriate
treatment, control the spread of infection and prevent
adverse outcomes of STIs [9].
Where testing is available in LMICs, it typically uses
technologies that require strong laboratory-based infra-
structure and well-trained laboratory technicians. In
addition, test turnaround time (TAT) is often long, re-
quiring patients to return for test results on a subse-
quent clinic visit. However, in LMICs STI testing is
often unavailable, expensive, and inaccessible. Point-of-
care tests (POCTs) have shorter TATs, allowing for
diagnosis and treatment in the same visit [10].
With the exception of some POCTs for the serodiag-
nosis of syphilis (treponemal component, single or du-
plex with HIV), no currently available STI POCT meets
all of the so-called REASSURED criteria: none has
adequate real-time connectivity and ease of specimen
collection and is sufficiently affordable, sensitive, spe-
cific, user-friendly, rapid/robust, equipment free and de-
liverable to those who need them [11]. Currently, the
test performance of CT, NG, and TV POCTs generally
suffers from poor sensitivity [7]. However, sample in/an-
swer out nucleic acid amplification tests (NAATs) offer
improved performance for patient management and im-
proved surveillance through data transmission capabil-
ities. Such molecular tests for CT, NG, TV and HPV are
already available, but too expensive for resource con-
strained settings. The World Health Organization
(WHO) recommends the use of NAATs for screening/
regular testing for asymptomatic STIs in key popula-
tions; this recommendation is conditional because the
cost of NAATs is prohibitive for its availability [9].
Despite the current lack of availability of such tests,
the increased attention of manufacturers on STI POCTs
in recent years has resulted in a reasonably strong pipe-
line for such platforms suitable for use in LMICs, as evi-
denced by the latest landscape in STI POC diagnostics
[11]. However, continued support for pipeline technolo-
gies is needed. This includes technical guidance, finan-
cial support and ongoing advocacy.
A target product profile (TPP) provides technical guid-
ance for the development of health products, including
in vitro diagnostics. WHO develops TPPs to fill the gaps
of the most urgent public health needs, including con-
cepts of access, equity and affordability as integral parts
at each stage of the development process for new prod-
ucts [12]. In general, the WHO TPP development
process consists of the following standard procedures: (i)
conducting a needs assessment; (ii) appointing a TPP
scientific development group; (iii) drafting an initial TPP
to be revised by the development group; (iv) posting and
distributing a revised draft TPP for public consultation;
(v) revising and finalizing the TPP, often by convening
the development group; and (vi) disseminating the final,
consensus-based TPP via the WHO website and other
channels.
Diagnostics are an essential component of the global
priorities of the WHO. Guided by the WHO Global
Strategy for the Control and Prevention of STIs,
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recognizing the importance of POCTs [4], the WHO
Department of Sexual and Reproductive Health and Re-
search (SRH), has developed target product profiles
(TPPs) to support and accelerate the development of
new STI POCTs for CT, NG, TV, syphilis and HPV, and
to encourage a better fit between future STI platforms/
tests and health needs in LMICs. The TPPs set out both
minimal and desired performance and operational char-
acteristics, including among other things, intended use
and setting, target user, and instrument specifications.
The TPPs, originally developed in 2016 are currently be-
ing updated [13].
This commentary describes the results of a survey
among diagnostic manufacturers about the relevance
and impact of the TPPs in their development framework
as well as ways in which TPPs may be improved.
Methods
In 2019, as part of the consensus-building process for re-
vising the 2016 STI POCT TPPs, a brief survey was con-
ducted among companies that manufacture or are
developing one or more STI POCTs. Companies were
selected for the survey from the most recent STI POCT
diagnostics landscape commissioned by the WHO and
available at: https://www.who.int/reproductivehealth/
topics/rtis/Diagnostic-Landscape-for-STIs-2019.pdf [11,
13]. Of those approximately 25 companies, 18 compan-
ies were surveyed, including those developing/manufac-
turing multiplex diagnostics – i.e., those that provide, or
will provide, testing for more than one infection (e.g.,
CT and NG) simultaneously or serially. The companies
chosen are a representative sample of diagnostic com-
panies developing or manufacturing POCTs for STIs
and include both large and small diagnostic companies
with POCTs for STIs already in the market as well as
those with products in the pipeline.
Representatives of each of the 18 companies were con-
tacted via email with follow-up by telephone, if required.
Company representatives were generally senior scientific
officers, including chief executive and chief technology
officers. Representatives were asked to complete a short
questionnaire indicating: 1) whether they were aware of
the 2016 STI TPPs; 2) if not, what WHO could do to in-
crease awareness; 3) if they were aware of the TPPs,
whether they had consulted them; 4) if they consulted
the TPPs, what they found most useful about them; and
5) how the TPPs could be improved.
Due to the low number and high variability of respon-
dents, no statistical analysis was performed, and results
are presented in a narrative.
Results
Of the 18 companies contacted, 11 responded. The 11
respondent companies ranged from small start-ups to
very large, established diagnostic companies. Most com-
panies are developing or manufacturing NAAT-based
multiplex platforms for the diagnosis of CT and NG.
Some are also developing POCTs for TV and HPV. All
are designed for use in LMICs.
Of the 11 companies that completed the survey, 8
were aware of the WHO-developed TPPs, and 6 of them
had used them as a reference in developing their test
platforms.
Utility of TPPs
Overall, the respondents indicated that the STI TPPs
provided good guidance to companies with respect to
performance expectations as well as operational charac-
teristics for the tests/platforms. The summary of re-
quirements and characteristics found in the TPPs
provided a good basis for comparison with each com-
pany’s own findings with respect to its platform, includ-
ing required stability claims. In particular, optimal
metrics for sensitivity, specificity, sample types, and
TAT were considered to be very useful. The TPPs also
provided useful guidance to companies for the recom-
mended characteristics of tests required for use in
LMICs (e.g., heat/humidity/altitude tolerances, ease of
use, and cost).
Improve relevance
Companies offered suggestions for ways to increase
the relevance of and further refine the STI TPPs.
Comments included that it would be useful to indi-
cate the relative importance of each performance and
operational characteristic of the test platform and to
provide a rationale as to why certain characteristics
are considered important in which contexts. In other
words, the TPPs should prioritize the characteristics
as developers indicated it is not feasible to achieve
each and every desired standard. Developers often
make trade-offs between factors such as speed, ease-
of-use, and cost, among others. Companies also ad-
vised that TPPs should be more agnostic with respect
to the technologies to be used for the platform. Ra-
ther than specifying, for example, that the test is ex-
pected to be an instrument-based molecular platform,
allow that any technology and any innovative design/
embodiment that meets the described characteristics
in the TPP is acceptable. Companies noted the lack
of attention in these TPPs to resistance testing for
those infections where it is an important factor (e.g.,
NG). There are challenges for developers to identify
viable and potentially sustainable market opportunities
in LMICs. The manufacturers advised that TPPs
should also link to market and funding data, to help
them overcome these challenges.
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Improve industry awareness of the STI POCT TPPs
Manufacturers suggested that WHO should encourage
industry participation in the TPP development process
to enhance understanding of the process and the ration-
ale for suggested product attributes. They suggested that
WHO maintain and annually update a targeted email list
or Listserv of multiple contacts at diagnostic companies,
using this for distribution of STI POCT TPPs. Another
idea was to initiate a WHO communications plan with
respect to the TPPs, including publishing them in a
WHO newsletter or in the WHO Bulletin, giving them
visibility at professional meetings, and maintaining more
direct and frequent contact at the national level in-
country. More specifically, they called for the creation of
a WHO webpage specifically for industry that houses
TPPs and other documents relevant to diagnostic com-
panies and developers. Finally, it was also suggested that
consideration be given to developing regionalized TPPs
as well as TPPs for diagnostics for high income
countries.
In summary, the surveyed companies and developers
value the STI POCT TPPs and want them to continue.
In order to have maximum impact, there were several
consistent themes: refine the TPPs, include industry
more directly from the beginning of the process, and
find additional ways to publicize the TPPs.
Discussion
The WHO STI diagnostic landscapes have confirmed in-
creased development activity for STI POCTs over the
last 4–5 years, but also showed that additional plat-
forms/tests are needed. Ongoing support for develop-
ment in the form of technical guidance, financial
resources and advocacy is needed. One form of technical
guidance is the TPP. A brief survey with manufacturers
in regard to the 2016 TPPs for STI POCTs suggested
that the TPPs are useful to assist developers in designing
diagnostics that are a better fit for LMICs, but in order
to make them more relevant, should classify the import-
ance of characteristics, not specify the type of technol-
ogy, include characteristics for resistance and take
funding and markets into account. The manufacturers
also indicated ways to increase industry awareness of the
TPPs, using targeted publicity and by including industry
early on in the process.
The limitations of the survey include its small sample
size. Only a modest number (11) diagnostic developers/
manufacturers were surveyed with respect to the STI
TPPs. The survey employed a simple questionnaire in
order to get a snapshot of the current feedback on TPPs
for STI POCTs. Risks of bias include the high number of
non-respondents (7 out of 18) and the fact that compan-
ies very early in the development process for STI POC
diagnostics have not been included.
Nonetheless, the survey of companies developing STI
POCTs confirmed the relevance and importance of
TPPs. Suggestions by companies should be taken into
consideration for the WHO strategy for updating TPPs
for STIs. For example, WHO could consult with indus-
try on WHO’s proposed specifications for the TPPs (e.g.,
including anti-microbial resistance capabilities) and dis-
cuss with them what is most feasible for development,
incorporating changes to the TPPs as deemed appropri-
ate. WHO should intensify its advocacy efforts, broaden-
ing its communication, including both published articles
and targeted online strategies.
Future research to increase access to STI POCTs in
LMICs might want to explore the development and en-
couragement of new business models that are less con-
cerned with maximizing profit or return on investment.
Additionally, more research and tools are needed on
how to introduce STI POCTs into health policies and
integrate them in health systems in LMICs [7]. If more
country policies would actively strive to increase STI test-
ing for surveillance and spotting outbreaks early on, this
could eventually lead to advance purchase commitments
(APC), ensuring a market for STI POCTs. WHO could
work with key stakeholders and opinion leaders in-
country (e.g., ministries of health, regulatory authorities)
to advocate and provide their support in tackling the
challenges of implementation of POCTs.
Conclusions
The 2019 WHO survey of developers and manufacturers
of STI POCTs showed that manufacturers find the STI
diagnostic TPPs to be useful, but that they can be im-
proved. Industry indicated that it would like to be in-
cluded earlier in the process and that TPPs could be
more widely disseminated. WHO should continue to
play an important role in fostering the development of
POCTs for use in LMICs by regularly updating and
broadly disseminating its TPPs along with its STI diag-
nostics landscapes, but needs to take a deeper look into
how manufacturers can more meaningfully and trans-
parently be engaged.
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